Please login to the form below
Triple-negative breast cancer
This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Trodelvy set for EU approval in breast cancer
unresectable or metastatic triple-negative breast cancer (TNBC). ... Gilead’s development programme for Trodelvy includes potential use in other TNBC and metastatic urothelial cancer, for hormone receptor-positive/human epidermal growth factor receptor
Latest news
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... TNBC is an aggressive and hard-to-treat subtype of
-
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
The HER-Vaxx jab is a B-cell activating cancer immunotherapy designed to target tumours that overexpress the HER2/neu receptor in gastric, breast, ovarian, lung and pancreatic cancers. ... Elsewhere in Imugene’s pipeline are a phase 1 triple negative
-
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... Triple negative breast cancer is known to be particularly aggressive and fast growing, and after treatment the risk of recurrence is faster and higher than in any other
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
New trial data for Keytruda in triple-negative breast cancer
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
More from news
Approximately 8 fully matching, plus 73 partially matching documents found.
Latest Intelligence
-
Patient diversity in clinical trials needs to be centre stage
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
-
Pharma deals during February 2014
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
Patient diversity in clinical trials needs to be centre stage
Cortellis Drugs to Watch in 2020 report
Deal Watch February 2017
Pharma deals during February 2014
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
